Clinical Trial

Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea

Name: Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea — clinical trial record (NCT06998095)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Tezepelumab

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

The objectives of this study are to describe the incidence of adverse events and the effectiveness of tezepelumab in patients receiving tezepelumab as indicated for severe asthma or CRSwNP in South Korea.

Protocol Amendment History 1 change

critical Primary endpoint(s) modified 2026-06-05

Trial Details

NCT Number	NCT06998095
Lead Sponsor	AstraZeneca
Conditions	Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps(CRSwNP)
Enrollment	210 participants
Start Date	2026-11-28
Primary Completion	2029-10-31 (estimated)
Study Completion	2029-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-04